Search results for: 'projection'

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across structural heart therapies, diabetes and metabolic monitoring, interventional tools, surgical navigation, neuromodulation, surgical robotics, advanced wearables, and AI driven risk prediction and behavioral modelling.The issue f...

This study focuses on the global electrophysiology (EP) ablation devices market. It analyzes the market for catheter-based ablation technologies used primarily to treat cardiac arrhythmias (especially atrial fibrillation), including radiofrequency (RF), cryoablation, pulse field ablation (PFA), and emerging modalities.The global EP ablation devices...

This analysis explores the transformation of healthcare from reactive disease treatment toward proactive, continuous, and personalized health management driven by AI, digital health, and predictive intelligence. Rising chronic disease burdens, aging populations, and escalating healthcare costs are accelerating demand for early detection, continuous...

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for 1 in 3 deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is stron...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...